Financial Performance Highlights

Quarter Ended September 30, 2026 (Q2 FY2026):

  • Total Income: ₹2,842.55 lakhs (compared to ₹2,200.42 lakhs in Q2 FY2025)
  • Revenue from Operations: ₹2,788.49 lakhs
  • Other Income: ₹54.06 lakhs
  • Profit Before Tax: ₹200.99 lakhs (compared to ₹166.76 lakhs in Q2 FY2025)
  • Tax Expense: ₹53.09 lakhs (Current Tax: ₹50.59 lakhs, Deferred Tax: ₹2.50 lakhs)
  • Net Profit: ₹147.90 lakhs (compared to ₹122.28 lakhs in Q2 FY2025)
  • Basic EPS: ₹123.25 (compared to ₹101.90 in Q2 FY2025)
  • Diluted EPS: ₹123.25

Half Year Ended September 30, 2026 (H1 FY2026):

  • Total Income: ₹5,725.88 lakhs (compared to ₹4,591.07 lakhs in H1 FY2025)
  • Revenue from Operations: ₹5,620.76 lakhs
  • Other Income: ₹105.12 lakhs
  • Profit Before Tax: ₹418.99 lakhs (compared to ₹334.23 lakhs in H1 FY2025)
  • Tax Expense: ₹110.46 lakhs (Current Tax: ₹105.46 lakhs, Deferred Tax: ₹5.00 lakhs)
  • Net Profit: ₹308.53 lakhs (compared to ₹245.10 lakhs in H1 FY2025)
  • Basic EPS: ₹257.11 (compared to ₹204.25 in H1 FY2025)
  • Diluted EPS: ₹257.11

Expense Breakdown (Q2 FY2026)

  • Cost of Materials Consumed: ₹1,586.29 lakhs
  • Employee Benefits Expense: ₹242.55 lakhs
  • Finance Cost: ₹80.20 lakhs
  • Depreciation and Amortization: ₹180.00 lakhs
  • Other Expenses: ₹600.14 lakhs
  • Total Expenses: ₹2,641.56 lakhs

Balance Sheet Position (as at September 30, 2026)

  • Property, Plant and Equipment: ₹11,873.84 lakhs
  • Investment Property: ₹478.98 lakhs
  • Biological Assets: ₹27.22 lakhs
  • Financial Assets: ₹1,592.02 lakhs
  • Inventories: ₹1,606.95 lakhs
  • Trade Receivables: ₹1,788.34 lakhs
  • Cash and Cash Equivalents: ₹66.72 lakhs
  • Total Assets: Not fully quantified in disclosure

Capital Structure

  • Paid-up Equity Share Capital: ₹60.00 lakhs (Face Value ₹50 per share)
  • Other Equity: ₹13,052.78 lakhs (as at March 31, 2026)

Auditor's Review

M/s. R G B & Associates, Chartered Accountants (FRN No. 144967W) issued a limited review report stating that nothing has come to their attention that causes them to believe that the financial results contain any material misstatement. The review was conducted in accordance with Standard on Review Engagement (SRE) 2410.

Meeting Details

The Board meeting commenced at 02:00 PM and concluded at 02:45 PM on November 13, 2026.